Lupin Limited
LUPIN
Rangering i aksjer
#2107
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
Aksjekurs
$21.43
Markedsverdi
$9.80B
Endring (1 dag)
0.14%
Endring (1 år)
-2.88%
Land
IN
Handel Lupin Limited (LUPIN)
Kategori
Healthcare
P/S-forhold for Lupin Limited (LUPIN)
P/S-forhold per October 2026 TTM: 3.02
Ifølge Lupin Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 3.02. Ved slutten av 2024 hadde selskapet et P/S-forhold på 3.71.
P/S-historikk for Lupin Limited fra 2004 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 3.02 | -23.28% |
| 2025 | 3.94 | 6.24% |
| 2024 | 3.71 | 107.54% |
| 2023 | 1.79 | -13.98% |
| 2022 | 2.08 | -32.49% |
| 2021 | 3.08 | 74.64% |
| 2020 | 1.76 | -27.16% |
| 2019 | 2.42 | 7.19% |
| 2018 | 2.26 | -41.15% |
| 2017 | 3.84 | -21.44% |
| 2016 | 4.88 | -31.82% |
| 2015 | 7.16 | 90.00% |
| 2014 | 3.77 | 25.69% |
| 2013 | 3.00 | -10.14% |
| 2012 | 3.34 | 2.60% |
| 2011 | 3.25 | 10.85% |
| 2010 | 2.93 | 96.35% |
| 2009 | 1.49 | -0.60% |
| 2008 | 1.50 | -37.81% |
| 2007 | 2.42 | 0.70% |
| 2006 | 2.40 | 37.87% |
| 2005 | 1.74 | -18.90% |
| 2004 | 2.15 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 133.50% |
IN
|
